' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Nonresected non-small-cell lung cancer in Stages I through IIIB: accelerated, twice-daily, high-dose radiotherapy--a prospective Phase I/II trial with long-term follow-up.
Wurstbauer, K; Deutschmann, H; Kopp, P; Kranzinger, M; Merz, F; Nairz, O; Studnicka, M; Sedlmayer, F;
INT J RADIAT ONCOL. 2010; 77(5): 134-151.
Originalarbeiten (Zeitschrift)


Deutschmann Heinz
Sedlmayer Felix
Studnicka Michael
Wurstbauer Karl


Our purpose was to investigate the tolerability of accelerated, twice-daily, high-dose radiotherapy. The secondary endpoints were survival and locoregional tumor control.
Thirty consecutive patients with histologically/cytologically proven non-small-cell lung cancer were enrolled. Tumor Stage I, II, IIIA, and IIIB was found in 7, 3, 12, and 8 patients, respectively. We applied a median of 84.6 Gy (range, 75.6-90.0 Gy) to the primary tumors, 63.0 Gy (range, 59.4-72.0 Gy) to lymph nodes, and 45 Gy to nodes electively (within a region of about 6 cm cranial to macroscopically involved sites). Fractional doses of 1.8 Gy twice daily, with an interval of 11 hours, were given, resulting in a median treatment time of 35 days. In the majority of patients the conformal target-splitting technique was used. In 19 patients (63%) two cycles of induction chemotherapy were given. The median follow-up time of survivors is 72 months (range, 62-74 months).
We found Grade 1, 2 and 3 acute esophageal toxicity in 11 patients (37%), 2 patients (7%), and 2 patients (7%), respectively. Grade 2 acute pneumonitis was seen in 2 patients (7%). No late toxicity greater than Grade 1 was observed. The actual overall survival rates at 2 and 5 years are 63% and 23%, respectively; the median overall survival, 27.7 months. In 9 patients a local failure occurred, 7 of them presenting initially with an atelectasis without availability of 18-fluorodeoxyglucose-positron emission tomography staging at that time. In 4 patients recurrence occurred regionally.
This Phase I/II trial with long-term follow-up shows low toxicity with promising results for survival and locoregional tumor control.

Useful keywords (using NLM MeSH Indexing)


Aged, 80 and over

Carcinoma, Non-Small-Cell Lung/drug therapy

Carcinoma, Non-Small-Cell Lung/mortality

Carcinoma, Non-Small-Cell Lung/pathology

Carcinoma, Non-Small-Cell Lung/radiotherapy*

Esophagus/radiation effects


Follow-Up Studies


Lung Neoplasms/drug therapy

Lung Neoplasms/mortality

Lung Neoplasms/pathology

Lung Neoplasms/radiotherapy*


Middle Aged

Neoplasm Staging

Neoplasms, Second Primary/pathology

Radiation Injuries/complications

Radiation Injuries/pathology

Radiation Pneumonitis/etiology

Radiotherapy Dosage

Remission Induction/methods

Survival Rate

Find related publications in this database (Keywords)

Non small-cell lung cancer
Accelerated radiotherapy
Conformal radiotherapy
Target splitting
Phase I/II clinical trials